"We are initiating coverage of Evolent Health with an Outperform rating and $45 price target."
Goldman Sachs downgrades Estee Lauder to neutral from buy Goldman downgraded the stock and said it's under "sizeable pressure."
"We are upgrading Annexon (ANNX shares) to Overweight from Neutral and establishing a December 2024 price target of $11."
Bank of America reiterates Eli Lilly as buy Bank of America raised its price target on the stock to $1000 per share from $800.
"Following 4Q23 earnings we are upgrading GoodRx from Neutral to Overweight and increasing our December 2024 price target from $7 to $10."
Persons:
Davidson, Campbell, Morgan Stanley, JD, TD Cowen, Parker, Dell, Goldman Sachs, Goldman, Louise Singlehurst, Tom Ford, Jefferies, Root, AVGO's, Stephens, Vita Coco, COCO, Piper downgrades, Piper, Redburn, Oppenheimer, Daiwa, Morgan Stanley downgrades Flywire, Goldman Sachs downgrades Estee Lauder, Estee Lauder, Dwight, Wells, Eli Lilly, Lilly, D.A
Organizations:
Apple, Vulcan, Merck, Vertex Pharmaceuticals, Bank of America, Broadcom, York Community Bancorp, Netflix, Micron, Mizuho, MU, Citi, EV, Health, Nvidia, Dwight, Hewlett Packard Enterprises, JPMorgan, biosciences, " Bank of America
Locations:
York, Davidson, Oshkosh, Minneapolis , MN